Smart Biotech Scientist | Master Bioprocess CMC Development, Biologics Manufacturing & Scale-up for Busy Scientists David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado

How can you provide stress-free cultivation conditions to achieve higher cell concentrations and quality? In a nutshell, bionic bioreactors and thus change bubble-free gas exchange change the game.
Join us as we delve into the future of biotech with our guest, Patrick Bongartz, CEO of BioThrust and an expert in innovative bioreactor design.
Key Highlights:
Unveil the groundbreaking "artificial lung," a marvel of engineering that decouples mixing and gas transfer, enabling stress-free cell growth at unprecedented densities.From scaling issues to cell sensitivity, discover the hurdles that demand ingenious solutions.Explore the critical factors when handling sensitive cell types driving bioreactor evolution.Discover how bionic bioreactors are paving the way for a stress-free future in cell cultivation.
Connect with Patrick Bongartz:
Website: https://biothrust.de
Linkedin BioThrust https://www.linkedin.com/company/biothrust-de
Instagram: https://www.instagram.com/biothrust
Patrick’s LinkedIn: https://www.linkedin.com/in/patrick-bongartz-1106/
Next Step:
Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Does the process of commercializing cell and gene therapies seem complex and unclear to you?
Dive deep into the groundbreaking world of cell and gene therapies with our guest, Wajiha Ali, a strategy expert who believes in bridging the gap between research and commercialization with data, as we unravel the complexities of bringing life-saving therapies to patients.
From cutting-edge technologies to innovative collaboration models, we explore the future landscape of these transformative treatments.
You’ll get:
An understanding of how partnerships between academic centers, pharma companies, and regulators can decrease development costs and simplify commercialization, resulting in wider accessibility.An investigation into how data analytics, AI, and machine learning can transform supply chains, target selection, commercialization strategies, and regulatory frameworks.A discovery of new methods for equitable therapy access, such as outcome-based pricing, local manufacturing, and the growing role of digital platforms in patient advocacy.Join us on this insightful journey into the future of cell and gene therapies.
Connect with Wajiha Ali:
LinkedIn: https://www.linkedin.com/in/wajiha-ali-6468454
X (Twitter): https://twitter.com/Wajihaali
Next Step:
Develop biologics and cell & gene therapies with peace of mind. Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Are you finding the path to commercializing cell and gene therapies complex and uncertain?
Join us as we explore this intricate landscape with our guest, Wajiha Ali. As a strategy expert who believes in bridging the gap between research and commericalization with data who she will guide us through the challenges, victories, and vital strategies for successfully bringing these cutting-edge therapies to market.
Key Highlights:
Discover the amplified complexity of cell and gene therapies, from patient referral hurdles to manufacturing site regulations.Explore the crucial commercialization strategies, infrastructure requirements, and the delicate balance between innovation and necessity.Unveil the regulatory scrutiny and stakeholder management intricacies, paving the way for safer, more accessible therapies.Tune in as we navigate the journey from scientific breakthroughs to real-world application, unraveling the complexities shaping the future of healthcare.
Connect with Wajiha Ali:
LinkedIn: https://www.linkedin.com/in/wajiha-ali-6468454
X (Twitter): https://twitter.com/Wajihaali
Next Step:
Develop biologics and cell & gene therapies with peace of mind. Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

In the second part of "Decode Bioprocess Success: The Art of Stakeholder Management," we delve deeper into the strategies for effective stakeholder management in bioprocess development.
Through a step-by-step approach, we explore how to identify, classify, and engage with stakeholders to ensure project success.
Key highlights:
Learn how to create a stakeholder management plan tailored to the unique needs and interests of each stakeholder group.Discover the power interest grid, a valuable tool for categorizing stakeholders based on their level of influence and interest in the project.Gain insights into developing communication plans that align with stakeholders' preferences and needs.Join us as we uncover the art of stakeholder management and its transformative impact on bioprocess development success. Don't miss out on this episode filled with practical advice and actionable strategies for mastering stakeholder engagement in bioprocess projects.
Next Step:
Boost your bioprocess strategy! Book your free assessment for success: https://bruehlmann-consulting.com/assessment

In this episode, we embark on a journey to uncover the essential strategies for navigating stakeholder relationships in bioprocess CMC development projects.
We delve into the critical role of stakeholders in bioprocess development and how their engagement can determine the success or failure of a project. Drawing from real-life experiences and insights, we explore the importance of understanding stakeholder needs, interests, and power dynamics.
Discover why stakeholder management is not just a skill but an art form essential for unlocking bioprocess success. Join us as we unravel the complexities of stakeholder engagement and provide actionable tips for mastering this crucial aspect of bioprocess development.
Tune in to learn how decoding the dynamics of stakeholder management can lead to triumph in bioprocess projects.
Next Step:
Boost your bioprocess strategy! Book your free assessment for success: https://bruehlmann-consulting.com/assessment

Unlock the secrets to cost-efficient antibody therapeutics with Brian Kelley, Senior Vice President of Process Development at VIR Biotechnology.
In this illuminating episode, industry expert Brian Kelley shares invaluable insights into driving down manufacturing costs while maintaining quality and accessibility. From optimizing batch sizes to maximizing titers, discover practical strategies to streamline the process economics of antibody development.
Key Takeaways:
Scale Matters: Learn how economies of scale play a pivotal role in minimizing manufacturing costs, paving the way for global accessibility of life-saving therapies.Titer Triumphs: Dive deep into the significance of maximizing titers to achieve substantial reductions in batch requirements and cost of goods, revolutionizing antibody production efficiency.Focus Innovation: Gain clarity on where to direct innovation efforts, balancing established manufacturing practices with groundbreaking developments in emerging modalities like cell and gene therapies.Join us as we unravel the future landscape of antibody production, where simplicity and innovation converge to shape the next frontier of healthcare solutions. Tune in now for actionable strategies and visionary perspectives on mastering process economics in antibody therapeutics.
Connect with Brian Kelley:
LinkedIn: https://www.linkedin.com/in/brian-kelley-3389375
Next Step:
Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment